322 related articles for article (PubMed ID: 18632754)
1. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG
Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754
[TBL] [Abstract][Full Text] [Related]
2. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
3. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice.
Ju YH; Doerge DR; Allred KF; Allred CD; Helferich WG
Cancer Res; 2002 May; 62(9):2474-7. PubMed ID: 11980635
[TBL] [Abstract][Full Text] [Related]
4. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
[TBL] [Abstract][Full Text] [Related]
5. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
6. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Brodie AH; Jelovac D; Long B
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
[TBL] [Abstract][Full Text] [Related]
7. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
8. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
10. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Long BJ; Tilghman SL; Yue W; Thiantanawat A; Grigoryev DN; Brodie AM
J Steroid Biochem Mol Biol; 1998 Nov; 67(4):293-304. PubMed ID: 9883986
[TBL] [Abstract][Full Text] [Related]
11. Stopping treatment can reverse acquired resistance to letrozole.
Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
[TBL] [Abstract][Full Text] [Related]
12. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
13. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
[TBL] [Abstract][Full Text] [Related]
14. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations.
Ju YH; Allred KF; Allred CD; Helferich WG
Carcinogenesis; 2006 Jun; 27(6):1292-9. PubMed ID: 16537557
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral aromatase model: the effects of letrozole (CGS 20267).
Brodie A; Lu Q; Yue W; Wang J; Liu Y
Breast Cancer Res Treat; 1998; 49 Suppl 1():S23-6; discussion S33-7. PubMed ID: 9797014
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Long BJ; Jelovac D; Handratta V; Thiantanawat A; MacPherson N; Ragaz J; Goloubeva OG; Brodie AM
J Natl Cancer Inst; 2004 Mar; 96(6):456-65. PubMed ID: 15026471
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
18. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
19. Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
Wang J; Gildea JJ; Yue W
Oncogene; 2013 Oct; 32(44):5233-40. PubMed ID: 23178495
[TBL] [Abstract][Full Text] [Related]
20. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
